More than 80% (87/104) of participants had a lifetime history of suicidal ideation; 13 of 53 (24.5%) in the MDMA-AT group and 12 of 51 (23.5%) in the placebo with therapy group reported suicidal ideation during the final preparation session (V4). The number of participants reporting positive suicidal ideation varied throughout the study but collectively never exceeded baseline values in either group (Supplementary Fig. 2). Of these, one participant in the MDMA-AT group with no suicidal ideation at baseline had the emergence of active suicidal ideation with at least some intent to act. Following an initial phone screening, participants provided written informed consent and underwent further screening assessments for eligibility. Study staff contacted outside providers, ordered medical records, how long does mdma stay in body and conducted a physical examination, laboratory testing (including pregnancy and drug tests), electrocardiogram, and 1-min rhythm strip.
Opinion: FDA ruling on ecstasy for PTSD is a bad trip for suffering patients Washington Post
In total, 45% of MDMA-AP participants versus 30% of controls reported side effects during medication sessions. Odds of experiencing anxiety and jaw clenching during medication sessions were also higher in MDMA-AP than control participants. Based on dose-dependent reports 38, 41, jaw clenching may be more likely to occur when receiving a higher dose (125 or 150 mg).
Making Sense with Sam Harris: The Future of Psychedelic Medicine 2
In Phase 2 studies, although participants undergoing MDMA-AP had higher odds of experiencing side effects during and 7 days after medication sessions relative to placebo-AP participants, there was no difference in TEAEs. Moreover, the observed differences between active and placebo conditions were relatively modest. For Phase 3 studies, participants undergoing MDMA-AP had higher odds of experiencing any TEAE as well as thirteen different types of TEAEs compared with placebo. These findings should, however, be interpreted with caution; we identified marked shortcomings in published information on side effects, including heterogeneity and weaknesses in how side effects were defined, assessed, and reported. Indeed, the certainty of evidence was rated as very low or low for 6 of 8 primary outcomes, with 2 rated as moderate certainty.
- These findings confirm and extend the results observed in MAPP1 (ref. 12), with general consistency across endpoints.
- Five participants in the placebo group and three participants in the MDMA group reported adverse events of special interest (AESIs) of suicidal ideation, suicidal behavior or self-harm in the context of suicidal ideation.
- Clinical trial data were analyzed using the IBM SPSS Statistics® software (version 23.0).
- Efficacy of MDMA-AT for PTSD has also been demonstrated in one placebo-controlled phase 2 trial (31).
Experts Suggest MDMA Could Heal PTSD: Here’s How
The proportion of patients in the No PTSD state treated with MDMA-AT at these endpoints was graphically represented with the proportion of sample as the y-axis and time in months as the x-axis. Using the best-fit method (log model), proportions were extrapolated over time and extracted for a 1-year time point. The difference between the proportions of patients in the No PTSD state at the estimated time point and a previous time point was equally distributed between the Non-severe and Severe PTSD states. The same method was used to estimate transitioning rates between the model health states among patients treated with the placebo with therapy comparator. This was a feasibility study and therefore was not powered to detect statistical significance. The study design and sample size were based on Phase 2 studies of MDMA-assisted psychotherapy for PTSD treatment18,19,20; there was no prior MDMA research relevant to this population, or primary outcome measure to serve as a basis for power analysis.
Source data
The sponsor of this racially-diverse study will submit an application to the FDA for approval of MDMA-assisted therapy for PTSD. Because the agency has designated MDMA as a “breakthrough therapy” — a category for potentially promising treatments for serious or life-threatening conditions — the application should be evaluated quickly. However, in July of this year, Australia became the first country to allow psychiatrists to prescribe MDMA for the treatment of certain mental health conditions. For people with PTSD who benefit from this treatment, MDMA potentially enhances psychotherapy by “reducing sensations of fear, threat and negative emotions,” the authors write. According to Nyquvest, the psychotherapeutic approach here is called “inner-directed therapy” where the mental health professionals are specially trained to create an environment that supports the inner healing process of the person receiving MDMA therapy. “MDMA works by creating a sense of safety and connection with the therapist(s), which may enhance therapeutic processing of traumatic events from the past,” explains Nyquvest.
Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences
- The aim of this pilot study was to examine the safety and efficacy of MDMA-assisted psychotherapy, among patients with cancer or non-dementing neurological diseases, to alleviate anxiety and other psychiatric symptoms, including depression and poor sleep quality, related to an LTI.
- Univariate one-way sensitivity analysis (OWSA) was implemented in the model to denote which input parameters had the greatest impact on study findings.
- Dr. Herzberg offers individual and couple therapy, ketamine-assisted therapy, and psychedelic integration with a specialization in developmental trauma.
- Simply put, MDMA puts the patient in the right frame of mind to undergo intensive work with their therapist on an accelerated timeline, and the Mitchell study is one more piece of evidence showing just how much potential this treatment has.
- Similarly, although years of PTSD diagnosis or age of onset may affect treatment efficacy, no obvious relationship was seen here between duration or onset of PTSD diagnosis and treatment efficacy.
While these are both still Schedule I substances—drugs with high abuse potential and no currently accepted medical use—ongoing research efforts have found support for using these compounds in conjunction with therapy to treat various mental health conditions, including PTSD. The Veterans Health Administration’s (VHA) Office of Research Development (ORD) is funding research on psychedelic compounds in Veterans. Mounting evidence supports substituted phenethylamine 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) as a treatment for PTSD12,13.
Additional head-to-head studies will need to be conducted to evaluate whether this form of manualized therapy provides greater value in the treatment of PTSD than the current first-line cognitive behavioral therapy and prolonged exposure therapy treatments37. Approximately 4.7 million US veterans report a service-related disability34, costing the US government approximately $73 billion per year35. If you’ve been diagnosed with a severe form of PTSD and you’re interested in MDMA-assisted therapy, it’s important to remember that this treatment should be done only with expert help in a clinical setting.
Verbora said about half of his colleagues who were pursuing psychedelic-assisted therapy for their patients have left the space. Last month, Moureaux was denied further access to psilocybin, because Health Canada said there’s no evidence of efficacy beyond five treatments. It suggested she participate in a process called an open-label individual patient study, essentially a clinical trial for a single person.